NCT06625710View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

December 30, 2025

Conditions

Neuro-Degenerative Disease

Interventions

DRUG

GV1001

Lyophilized peptide from hTERT

DRUG

Placebo

0.9 % Normal Saline

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

GemVax & Kael

INDUSTRY